Chemopreventive effect of celecoxib in gastric cancer

被引：30

作者：

Futagami S. ^{[1
]}

Suzuki K. ^{[1
]}

Hiratsuka T. ^{[1
]}

Shindo T. ^{[1
]}

Hamamoto T. ^{[1
]}

Ueki N. ^{[1
]}

Kusunoki M. ^{[1
]}

Miyake K. ^{[1
]}

Gudis K. ^{[1
]}

Tsukui T. ^{[1
]}

Sakamoto C. ^{[1
]}

机构：

[1] Third Department of Internal Medicine, Nippon Medical School, Bunkyo-ku, Tokyo 113-8602

来源：

Inflammopharmacology | 2007年 / 15卷 / 1期

关键词：

Celecoxib; COX-2; inhibitor; Gastric cancer; H; pylori; Intestinal metaplasia;

D O I：

10.1007/s10787-006-1541-5

中图分类号：

学科分类号：

摘要：

COX (cyclooxygenase) is one of the key enzymes involved in the synthesis of a variety of prostaglandins (PGs), some of which have been strongly linked to inflammation. One of its two well-known isoforms, COX-2, is an inducible enzyme whose induction and expression is dynamically regulated by growth factors, mitogens, and tumor promoters. Several animal and clinical studies have reported the chemopreventive effect of celecoxib, a selective COX-2 inhibitor; and in particular, a few studies have shown that celecoxib prevents the development of gastric cancer. Administration of celecoxib also showed increases in cardiovascular risk and disruption of renal physiology. Therefore, studies hoping to clarify how selective COX-2 inhibitors modulate gastric cancer must keep in mind that coxibs have also been linked to serious cardiovascular events and disruption of renal physiology. © 2007 Birkhäuser Verlag.

引用

页码：1 / 4

页数：3

共 50 条

[1]

Barter D.C., Effects of nonsteroide anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition, Am. J. Med, 107, pp. 65-71, (1999)

[2]

Clive D.M., Stoff J.S., Renal syndromes associated with non-steroidal anti-inflammatory drugs, N. Engl. J. Med, 310, pp. 563-572, (1984)

[3]

Cyber B., Nonsteroidal anti -inflammatory drugs and gastrointcstinal discasc, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, pp. 343-357, (1998)

[4]

Dubois R.N., Abramson S.B., Crofford L., Et al., Cyclooxygenase in biology and disease, FASEB J, 12, pp. 1063-1073, (1998)

[5]

Farrow D.C., Vaughan T.L., Hansten P.D., Et al., Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epidemiol. Biomarkers Prev, 7, pp. 97-102, (1998)

[6]

FitzGerald G.A., Coxibs and cardiovascular disease, N. Engl. J. Med, 351, pp. 1709-1711, (2004)

[7]

FitzGerald G.A., Patrono C., The coxibs, selective inhibitors of cyclooxygenase-2, N. Engl. J. Med, 345, pp. 433-442, (2001)

[8]

Fu S., Ramanujam K.S., Wong A., Et al., Increased expression and cellular localization of inducible nitroic oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis, Gastroenterology, 116, pp. 1319-1329, (1999)

[9]

Fu S.L., Wu Y.L., Zhang Y.P., Et al., Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer, World J. Gastroenterol, 10, pp. 1971-1974, (2004)

[10]

Futagami S., Hiratsuka T., Wada K., Et al., Inhibition of Helicobacter pylori-induced cyclooxygenase-2 aggravates NSAID-caused gastric damage in Mongolian gerbils, Aliment Pharmacol. Ther, 16, pp. 847-855, (2002)

← 1 2 3 4 5 →